Physician profile
Leigh E Higgins
NPI 1326496340
$10,020.54
in general payments reported to CMS, 2019-2025
24 companies · $2,948 in 2025
The $2,948 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $704 · 2022: $1,958 · 2023: $2,243 · 2024: $2,169 · 2025: $2,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,997 · Consulting Fee: $1,000 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,997.20 |
| Consulting Fee | $1,000.00 |
| Education | $361.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,214.38 | 2021-2025 | Opzelura |
| Abbvie INC. | $2,184.16 | 2021-2025 | |
| Genzyme Corporation | $1,370.62 | 2021-2025 | |
| Janssen Biotech, INC. | $841.23 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $577.76 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $553.03 | 2021-2023 | Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $443.61 | 2021-2025 | |
| Lilly USA, LLC | $261.48 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $235.17 | 2021-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $234.99 | 2023-2024 | |
| Ucb, INC. | $190.36 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $143.21 | 2023-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.45 | 2021-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $133.52 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $120.16 | 2022-2024 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $113.27 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.69 | 2023-2024 | Cyltezo, Spevigo |
| Pfizer INC. | $43.69 | 2022-2023 | |
| Organon LLC | $35.40 | 2024-2025 | Vtama |
| Merck Sharp & Dohme LLC | $26.84 | 2023 | Keytruda |
| Sandoz INC. | $24.87 | 2023 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $19.86 | 2021 | |
| Kerecis Limited | $18.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Dermira, INC. | $17.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.